Skip to main content
Addgene

R777-E139 Hs.NF1 Citations (9)

Originally described in: Esposito lab
Unpublished

Articles Citing R777-E139 Hs.NF1

Articles
Neurofibromin (NF1) genetic variant structure-function analyses using a full-length mouse cDNA. Wallis D, Li K, Lui H, Hu K, Chen MJ, Li J, Kang J, Das S, Korf BR, Kesterson RA. Hum Mutat. 2018 Jun;39(6):816-821. doi: 10.1002/humu.23421. Epub 2018 Apr 10. PubMed
Construction of cloning-friendly minigenes for mammalian expression of full-length human NF1 isoforms. Cui Y, Morrison H. Hum Mutat. 2018 Nov 8. doi: 10.1002/humu.23681. PubMed

Associated Plasmids
Affinity Purification of NF1 Protein-Protein Interactors Identifies Keratins and Neurofibromin Itself as Binding Partners. Carnes RM, Kesterson RA, Korf BR, Mobley JA, Wallis D. Genes (Basel). 2019 Aug 28;10(9). pii: genes10090650. doi: 10.3390/genes10090650. PubMed
A systems mechanism for KRAS mutant allele-specific responses to targeted therapy. McFall T, Diedrich JK, Mengistu M, Littlechild SL, Paskvan KV, Sisk-Hackworth L, Moresco JJ, Shaw AS, Stites EC. Sci Signal. 2019 Sep 24;12(600). pii: 12/600/eaaw8288. doi: 10.1126/scisignal.aaw8288. PubMed
Mutation-Directed Therapeutics for Neurofibromatosis Type I. Leier A, Bedwell DM, Chen AT, Dickson G, Keeling KM, Kesterson RA, Korf BR, Marquez Lago TT, Muller UF, Popplewell L, Zhou J, Wallis D. Mol Ther Nucleic Acids. 2020 Jun 5;20:739-753. doi: 10.1016/j.omtn.2020.04.012. Epub 2020 Apr 29. PubMed
The cryo-EM structure of the human neurofibromin dimer reveals the molecular basis for neurofibromatosis type 1. Lupton CJ, Bayly-Jones C, D'Andrea L, Huang C, Schittenhelm RB, Venugopal H, Whisstock JC, Halls ML, Ellisdon AM. Nat Struct Mol Biol. 2021 Dec;28(12):982-988. doi: 10.1038/s41594-021-00687-2. Epub 2021 Dec 9. PubMed
Identification of RAS mutant biomarkers for EGFR inhibitor sensitivity using a systems biochemical approach. McFall T, Stites EC. Cell Rep. 2021 Dec 14;37(11):110096. doi: 10.1016/j.celrep.2021.110096. PubMed
High-risk neuroblastoma with NF1 loss of function is targetable using SHP2 inhibition. Cai J, Jacob S, Kurupi R, Dalton KM, Coon C, Greninger P, Egan RK, Stein GT, Murchie E, McClanaghan J, Adachi Y, Hirade K, Dozmorov M, Glod J, Boikos SA, Ebi H, Hao H, Caponigro G, Benes CH, Faber AC. Cell Rep. 2022 Jul 26;40(4):111095. doi: 10.1016/j.celrep.2022.111095. PubMed
Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization. Young LC, Goldstein de Salazar R, Han SW, Huang ZYS, Merk A, Drew M, Darling J, Wall V, Grisshammer R, Cheng A, Allison MR, Sale MJ, Nissley DV, Esposito D, Ognjenovic J, McCormick F. Proc Natl Acad Sci U S A. 2023 Jan 31;120(5):e2208960120. doi: 10.1073/pnas.2208960120. Epub 2023 Jan 23. PubMed

If you have published an article using this material, please email us at [email protected] to have your article added to this page.